Diabetic kidney disease: act now or pay later

被引：9

作者：

Atkins, Robert C.

Zimmet, Paul

机构：

来源：

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION | 2010年 / 4卷 / 01期

关键词：

RISK-FACTORS; TYPE-2; NEPHROPATHY; PREVALENCE; MICROALBUMINURIA; IRBESARTAN; MELLITUS; OUTCOMES; OBESITY;

D O I：

10.1016/j.jash.2009.12.001

中图分类号：

R6 [外科学];

学科分类号：

100210 [外科学];

摘要：

引用

页码：3 / 6

页数：4

共 28 条

[1]

Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].

Adler, AI ;

Stevens, RJ ;

Manley, SE ;

Bilous, RW ;

Cull, CA ;

Holman, RR .

KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232

[2]

Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? [J].

Bilous, R. .

DIABETIC MEDICINE, 2008, 25 :25-29

[3]

Novel therapies of diabetic nephropathy [J].

Burney, Basil O. ;

Kalaitzidis, Rigas G. ;

Bakris, George L. .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (02) :107-111

[4]

The rising prevalence of diabetes and impaired glucose tolerance - The Australian diabetes, obesity and lifestyle study [J].

Dunstan, DW ;

Zimmet, PZ ;

Welborn, TA ;

de Courten, MP ;

Cameron, AJ ;

Sicree, RA ;

Dwyer, T ;

Colagiuri, S ;

Jolley, D ;

Knuiman, M ;

Atkins, R ;

Shaw, JE .

DIABETES CARE, 2002, 25 (05) :829-834

[5]

Effect of a multifactorial intervention on mortality in type 2 diabetes [J].

Gaede, Peter ;

Lund-Andersen, Henrik ;

Parving, Hans-Henrik ;

Pedersen, Oluf .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591

[6]

10-year follow-up of intensive glucose control in type 2 diabetes [J].

Holman, Rury R. ;

Paul, Sanjoy K. ;

Bethel, M. Angelyn ;

Matthews, David R. ;

Neil, H. Andrew W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589

[7]

International Diabetes Federation and International Society of Nephrology, 2003, DIAB KIDN DIS TIM AC

[8]

Global burden of diabetes, 1995-2025 - Prevalence, numerical estimates, and projections [J].

King, H ;

Aubert, RE ;

Herman, WH .

DIABETES CARE, 1998, 21 (09) :1414-1431

[9]

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

[10]

Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37

← 1 2 3 →